RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SAB Biotherapeutics Stock

SAB Biotherapeutics Revenue 2024

SAB Biotherapeutics Revenue

1.41 M USD

Ticker

SABS

ISIN

US78397T1034

In 2024, SAB Biotherapeutics's sales reached 1.41 M USD, a -37.07% difference from the 2.24 M USD sales recorded in the previous year.

The SAB Biotherapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e107.93-
2028e--
2027e--
2026e1.28-
2025e1.02-
2024e1.41-
20232.24-
202223.9-
202160.88-
202055.24-

SAB Biotherapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SAB Biotherapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SAB Biotherapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SAB Biotherapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SAB Biotherapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SAB Biotherapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SAB Biotherapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SAB Biotherapeutics’s growth potential.

SAB Biotherapeutics Revenue, EBIT and net profit per share

DateSAB Biotherapeutics RevenueSAB Biotherapeutics EBITSAB Biotherapeutics Net Income
2029e107.93 M undefined0 undefined0 undefined
2028e0 undefined-82.3 M undefined0 undefined
2027e0 undefined-78.38 M undefined0 undefined
2026e1.28 M undefined-57.94 M undefined-248.44 M undefined
2025e1.02 M undefined-50.75 M undefined-268.51 M undefined
2024e1.41 M undefined-44.78 M undefined-342.07 M undefined
20232.24 M undefined-37.98 M undefined-42.19 M undefined
202223.9 M undefined-28.8 M undefined-18.74 M undefined
202160.88 M undefined-13.39 M undefined-17.15 M undefined
202055.24 M undefined20.56 M undefined20.12 M undefined

SAB Biotherapeutics stock margins

The SAB Biotherapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SAB Biotherapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SAB Biotherapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SAB Biotherapeutics's sales revenue. A higher gross margin percentage indicates that the SAB Biotherapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SAB Biotherapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SAB Biotherapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SAB Biotherapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SAB Biotherapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SAB Biotherapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SAB Biotherapeutics Margin History

SAB Biotherapeutics Gross marginSAB Biotherapeutics Profit marginSAB Biotherapeutics EBIT marginSAB Biotherapeutics Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %-4,544.56 %-19,485.31 %
2025e0 %-4,975 %-26,324.82 %
2024e0 %-3,177.88 %-24,277.67 %
20230 %-1,696.07 %-1,884.5 %
20220 %-120.47 %-78.4 %
20210 %-22 %-28.16 %
20200 %37.22 %36.42 %

SAB Biotherapeutics Aktienanalyse

What does SAB Biotherapeutics do?

SAB Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding SAB Biotherapeutics's Sales Figures

The sales figures of SAB Biotherapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing SAB Biotherapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize SAB Biotherapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in SAB Biotherapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about SAB Biotherapeutics stock

How much revenue did SAB Biotherapeutics generate this year?

SAB Biotherapeutics has achieved a revenue of 1.41 M USD this year.

How much was the turnover of the company SAB Biotherapeutics compared to the previous year?

The revenue of SAB Biotherapeutics has increased by -37.07% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of SAB Biotherapeutics?

The revenue of SAB Biotherapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of SAB Biotherapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of SAB Biotherapeutics so important for investors?

The revenue of SAB Biotherapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does SAB Biotherapeutics pay?

Over the past 12 months, SAB Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SAB Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SAB Biotherapeutics?

The current dividend yield of SAB Biotherapeutics is .

When does SAB Biotherapeutics pay dividends?

SAB Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SAB Biotherapeutics?

SAB Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of SAB Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SAB Biotherapeutics located?

SAB Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SAB Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SAB Biotherapeutics from 11/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/15/2024.

When did SAB Biotherapeutics pay the last dividend?

The last dividend was paid out on 11/15/2024.

What was the dividend of SAB Biotherapeutics in the year 2023?

In the year 2023, SAB Biotherapeutics distributed 0 USD as dividends.

In which currency does SAB Biotherapeutics pay out the dividend?

The dividends of SAB Biotherapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SAB Biotherapeutics

Our stock analysis for SAB Biotherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SAB Biotherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.